Jose Baselga

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer
    Jose Baselga
    Jose Baselga, Memorial Sloan Kettering Cancer Center, New York, NY Javier Cortés, Vall d Hebron University Hospital, Barcelona, Spain Seock Ah Im, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea Emma Clark and Graham Ross, Roche Products, Welwyn Garden City, United Kingdom Astrid Kiermaier, F Hoffmann La Roche, Basel, Switzerland and Sandra M Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC
    J Clin Oncol 32:3753-61. 2014
  2. doi request reprint Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
    Jose Baselga
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Clin Oncol 31:2586-92. 2013
  3. doi request reprint Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 18:6364-72. 2012
  4. pmc Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab
    Jeonghee Cho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
    Mol Cancer 13:141. 2014
  5. pmc A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial
    Jose Baselga
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Trials 14:228. 2013
  6. doi request reprint Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer
    Javier Cortes
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 30:1594-600. 2012
  7. ncbi request reprint Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting
    Pablo Matar
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 10:6487-501. 2004
  8. doi request reprint Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
    Hatem A Azim
    Jose Baselga, Memorial Sloan Kettering Cancer Center, NY James G Greger Jr, GlaxoSmithKline, Collegeville, PA Hatem A Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles Phuong Dinh, Breast International Group, Brussels Peter Vuylsteke, Sint Elisabeth Hospital, Namur, Belgium Dominique Agbor tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain Christian Jackisch, Kilinikum Offenbach, Offenbach Bahriye Aktas, Kliniken Essen Mitte, Evang,
    J Clin Oncol 31:4504-11. 2013
  9. pmc Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
    Maurizio Scaltriti
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 16:2688-95. 2010
  10. doi request reprint Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Clin Oncol 30:1484-91. 2012

Collaborators

Detail Information

Publications70

  1. doi request reprint Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer
    Jose Baselga
    Jose Baselga, Memorial Sloan Kettering Cancer Center, New York, NY Javier Cortés, Vall d Hebron University Hospital, Barcelona, Spain Seock Ah Im, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea Emma Clark and Graham Ross, Roche Products, Welwyn Garden City, United Kingdom Astrid Kiermaier, F Hoffmann La Roche, Basel, Switzerland and Sandra M Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC
    J Clin Oncol 32:3753-61. 2014
    ....
  2. doi request reprint Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
    Jose Baselga
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Clin Oncol 31:2586-92. 2013
    ..Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of breast cancer. Our randomized phase II study investigated cisplatin with or without cetuximab in this setting...
  3. doi request reprint Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 18:6364-72. 2012
    ....
  4. pmc Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab
    Jeonghee Cho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
    Mol Cancer 13:141. 2014
    ..However, detailed mechanisms and genomic predictors for pharmacological response to these antibodies in colon cancer remain unclear...
  5. pmc A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial
    Jose Baselga
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Trials 14:228. 2013
    ..Here we describe RESILIENCE - a multinational, double-blind, randomized, placebo-controlled, phase 3 trial - assessing the addition of sorafenib to first- or second-line capecitabine in advanced HER2-negative breast cancer...
  6. doi request reprint Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer
    Javier Cortes
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 30:1594-600. 2012
    ..We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy...
  7. ncbi request reprint Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting
    Pablo Matar
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 10:6487-501. 2004
    ....
  8. doi request reprint Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
    Hatem A Azim
    Jose Baselga, Memorial Sloan Kettering Cancer Center, NY James G Greger Jr, GlaxoSmithKline, Collegeville, PA Hatem A Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles Phuong Dinh, Breast International Group, Brussels Peter Vuylsteke, Sint Elisabeth Hospital, Namur, Belgium Dominique Agbor tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain Christian Jackisch, Kilinikum Offenbach, Offenbach Bahriye Aktas, Kliniken Essen Mitte, Evang,
    J Clin Oncol 31:4504-11. 2013
    ....
  9. pmc Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
    Maurizio Scaltriti
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 16:2688-95. 2010
    ..We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting...
  10. doi request reprint Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Clin Oncol 30:1484-91. 2012
    ..A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer...
  11. pmc AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
    Sarat Chandarlapaty
    Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 19:58-71. 2011
    ..Consistent with this model, we find that, in tumors in which AKT suppresses HER3 expression, combined inhibition of AKT and HER kinase activity is more effective than either alone...
  12. doi request reprint Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
    Jose Baselga
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, Barcelona, Spain
    J Clin Oncol 27:2630-7. 2009
    ..This study explored whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001)...
  13. pmc Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
    Arkaitz Carracedo
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cell Cycle 7:3805-9. 2008
    ..In this extra-view, we integrate our findings into the mTORC1 signaling network and discuss its relevance for the design of combinatorial therapies with mTORC1 inhibitors...
  14. pmc Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study
    Sandra M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC 20010, USA
    Oncologist 18:257-64. 2013
    ..We report cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel observed in the phase III study CLEOPATRA in patients with HER2-positive first-line metastatic breast cancer (MBC)...
  15. doi request reprint Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study
    Javier Cortes
    Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 15:307-14. 2009
    ....
  16. doi request reprint Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib
    Susana Cedres
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Lung Cancer 66:257-61. 2009
    ..Inhibition of the EGFR pathway is a useful strategy in the treatment of patients with advanced NSCLC. The aim of this study is to assess predictive clinical parameters of efficacy...
  17. doi request reprint Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Jose Baselga
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Lancet 379:633-40. 2012
    ..We argue that the two anti-HER2 agents given together would be better than single-agent therapy...
  18. doi request reprint A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
    Francesco Atzori
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 17:6304-12. 2011
    ..This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose...
  19. pmc Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
    Sandra M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC 20010, USA
    Lancet Oncol 14:461-71. 2013
    ..Interim analysis of overall survival favoured the pertuzumab group but was not significant. Here, we report results for overall survival after an additional year of follow-up...
  20. pmc Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona, Spain E 08035
    J Clin Oncol 28:1138-44. 2010
    ..This phase II trial assessed the efficacy and safety profile of the combination in patients with HER2-positive breast cancer whose disease had progressed during prior trastuzumab-based therapy...
  21. pmc Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience
    Otto Metzger-Filho
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue Yawkey, Boston, 1238, USA
    Breast Cancer Res Treat 155:127-32. 2016
    ..We argue that prospective collection of treatment information beyond disease progression should be included in future clinical studies. ..
  22. ncbi request reprint Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
    Emiliano Calvo
    Vall d Hebron University Hospital, Universidad Autonoma de Barcelona, Barcelona, Spain
    J Clin Oncol 24:2158-63. 2006
    ..Therefore, in clinical trials with tyrosine kinase inhibitors and other molecular-targeted therapies, the inclusion of a global population appears to be required...
  23. doi request reprint NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
    ..In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha...
  24. pmc mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
    Vanessa S Rodrik-Outmezguine
    Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Discov 1:248-59. 2011
    ..These findings reveal the adaptive capabilities of oncogenic signaling networks and the limitations of monotherapy for inhibiting feedback-regulated pathways...
  25. doi request reprint Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel
    Javier Cortes
    aVall d Hebron University Hospital, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain bMedStar Washington Hospital Center, Washington Cancer Institute, Washington, District of Columbia cMid Ohio Oncology Hematology Inc, The Mark H Zangmeister Center, Columbus, Ohio dGenentech, South San Francisco, California eMemorial Sloan Kettering Cancer Center, New York, New York, USA fRiga East University Hospital Oncology Center, Riga, Latvia gDaugavpils Re and gacute ionālā Slimnīca, Daugavpils, Latvia hGesundheitszentrum Fricktal, Spital Rheinfelden and Laufenburg, Rheinfelden, Switzerland iNational Hospital Organization Osaka National Hospital, Osaka City, Osaka, Japan jRoche Products Limited, Welwyn Garden City, UK kPharsight, Montreal, Quebec, Canada
    Anticancer Drugs 24:1084-92. 2013
    ..In conclusion, no PK DDI was observed when pertuzumab, trastuzumab, and docetaxel were combined for the treatment of HER2-positive metastatic breast cancer. ..
  26. doi request reprint Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    Jose Baselga
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 366:520-9. 2012
    ..In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity...
  27. ncbi request reprint 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis
    Federico Rojo
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 13:81-9. 2007
    ....
  28. doi request reprint Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial
    Otto Metzger-Filho
    Dana Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 31:1954-60. 2013
    ..To evaluate the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) -positive invasive lobular carcinoma (ILC) enrolled onto the Herceptin Adjuvant (HERA) trial...
  29. pmc Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA
    Sandra M Swain
    Washington Cancer Institute, Medstar Washington Hospital Center, Washington, D C, USA Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Division of Hematology and Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea Veterans Memorial Medical Center, Cancer Research Center, Quezon City, Philippines Mount Vernon Cancer Centre, Middlesex, United Kingdom Roche Products Ltd, Welwyn Garden City, United Kingdom Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, New York, USA
    Oncologist 19:693-701. 2014
    ....
  30. doi request reprint Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
    Geoffrey I Shapiro
    Authors Affiliations Dana Farber Cancer Institute Massachusetts General Hospital Beth Israel Deaconess Medical Center, Boston, Massachusetts Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain Mary Crowley Cancer Research Centers, Dallas, Texas Exelixis Inc, South San Francisco, California and Sanofi, Cambridge, Massachusetts, and Vitry sur Seine, France
    Clin Cancer Res 20:233-45. 2014
    ....
  31. doi request reprint Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer
    Jose Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 27:526-34. 2009
    ..Gene expression studies were undertaken using genes that were identified as potentially associated with sensitivity/resistance to ixabepilone in prior preclinical investigations...
  32. doi request reprint Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 366:109-19. 2012
    ....
  33. ncbi request reprint 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications
    Gemma Armengol
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 67:7551-5. 2007
    ..Further investigation into this concept may identify additional funnel factors in the oncogenic pathways and provide potential therapeutic targets...
  34. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain corrected
    J Clin Oncol 23:2521-33. 2005
    ....
  35. pmc mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
    Moshe Elkabets
    Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA
    Sci Transl Med 5:196ra99. 2013
    ..Our findings suggest that simultaneous administration of mTORC1 inhibitors may enhance the clinical activity of p110α-targeted drugs and delay the appearance of resistance...
  36. doi request reprint A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
    Enriqueta Felip
    Medical Oncology Service and Pathology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 14:3867-74. 2008
    ..To examine potential markers of clinical benefit and the effects of erlotinib on the epidermal growth factor receptor (EGFR) signaling pathway in advanced non-small cell lung cancer patients refractory to platinum-based chemotherapy...
  37. doi request reprint Targeted therapies in breast cancer: where are we now?
    Serena Di Cosimo
    Medical Oncology Program, Medical Oncology Department, Vall d Hebron University Hospital, Passeig Vall d Hebron, Barcelona, Spain
    Eur J Cancer 44:2781-90. 2008
    ..We will present these novel therapies and will analyse for each target the developmental status of some of the agents as well as target-specific challenges...
  38. doi request reprint High HER2 expression correlates with response to the combination of lapatinib and trastuzumab
    Maurizio Scaltriti
    Human Oncology and Pathogenesis Program HOPP, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 21:569-76. 2015
    ..In this work, we aimed to investigate whether the levels of p95HER2 and HER2 can predict response to anti-HER2 therapy in patients with breast cancer...
  39. doi request reprint USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma
    Pieter J A Eichhorn
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Nat Med 18:429-35. 2012
    ..Our results show that USP15 regulates the TGF-β pathway and is a key factor in glioblastoma pathogenesis...
  40. ncbi request reprint Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
    Federico Rojo
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 24:4309-16. 2006
    ..The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study...
  41. ncbi request reprint Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer
    Jose Baselga
    Vall d Hebron University Hospital, Oncology Service, Barcelona, Spain
    Oncologist 11:4-12. 2006
    ..Overall, results from clinical trials are sufficiently compelling to consider 1 year of adjuvant trastuzumab treatment for women with HER-2-positive EBC based on the risk:benefit ratio demonstrated in these studies...
  42. pmc Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis
    Austin M Dulak
    Departments of Medical Oncology, Cancer Biology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer Res 72:4383-93. 2012
    ..Together, our results defined genomic features that were common and distinct to various gut-derived adenocarcinomas, potentially informing novel opportunities for targeted therapeutic interventions...
  43. doi request reprint CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Breast Cancer 10:489-91. 2010
    ..Combining trastuzumab and pertuzumab therefore provides a more comprehensive blockade of the HER signaling pathways, resulting in greater antitumor efficacy...
  44. pmc Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience
    Otto Metzger-Filho
    Division of Women s Cancers, Dana Farber Cancer Institute, 450 Brookline Avenue, Yawkey Building 1238, Boston, MA 02215, USA
    Oncologist 18:134-40. 2013
    ..This study measured the time taken for setting up the different facets of adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO), an nternational phase III study being conducted in 44 participating countries...
  45. pmc Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
    Adam J Bass
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 43:964-8. 2011
    ..This study shows previously unidentified levels of genomic rearrangements in colorectal carcinoma that can lead to essential gene fusions and other oncogenic events...
  46. doi request reprint Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?
    Serena Di Cosimo
    Medical Oncology Department, Vall d Hebron Institute of Oncology VHIO, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 15:5017-9. 2009
    ..These findings will have to be considered in the design and interpretation of clinical trials with inhibitors of the PI3K pathway...
  47. doi request reprint Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation
    Violeta Serra
    1Vall d Hebron Institut d Oncologia 2Vall d Hebron Institut de Recerca 3Institució Catalana de Recerca i Estudis Avançats ICREA, Barcelona 4Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain and 5Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer Discov 3:1238-44. 2013
    ..A symptomatic and radiologic clinical response was achieved. HER2V659E sensitivity to lapatinib was confirmed in the laboratory...
  48. doi request reprint Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
    Dejan Juric
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts
    Clin Cancer Res 21:2462-70. 2015
    ..The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of MEHD7945A...
  49. doi request reprint Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068
    Yibing Yan
    Authors Affiliations Oncology Biomarker Development, Portfolio Management and Operations, Translational Oncology, Biostatistics, and Exploratory Clinical Development, Genentech Inc, DNA Way, South San Francisco, California Experimental Therapeutics, Molecular Pathology, Breast Cancer and Melanoma, Gastrointestinal and Endocrine Tumors Groups, and Medical Oncology Service, Vall d Hebron Institute of Oncology, Barcelona Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain and Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 19:6976-86. 2013
    ..Therefore, we conducted pharmacodynamic studies with GDC-0068, an ATP competitive, selective Akt1/2/3 inhibitor, in preclinical models and in patients treated with this compound...
  50. pmc AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
    Moshe Elkabets
    Human Oncology and Pathogenesis Program HOPP, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA
    Cancer Cell 27:533-46. 2015
    ..Combined treatment with PI3Kα and either EGFR, AXL, or PKC inhibitors reverts this resistance. ..
  51. doi request reprint Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)
    Evandro de Azambuja
    Evandro de Azambuja and Martine J Piccart Genhart, Institut Jules Bordet Evandro de Azambuja, Breast European Adjuvant Study Team Martine J Piccart Gebhart, Universite Libre de Bruxelles, Brussels, Belgium Marion J Procter and Dominique Agbor Tarh, Frontier Science Scotland, Kincraig, Kingussie David A Cameron, University of Edinburgh and Western General Hospital, Edinburgh Ian E Smith, Royal Marsden Hospital and the Institute of Cancer Research Mitch Dowsett, The Royal Marsden National Health Service Trust, London, United Kingdom Dirk J van Veldhuisen, University of Groningen, Groningen, the Netherlands Otto Metzger Filho and Richard D Gelber, Dana Farber Cancer Institute, Boston, MA Jutta Steinseifer, F Hoffmann La Roche, Basel Thomas M Suter, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, Bern, Switzerland Michael Untch, HELIOS Klinikum Berlin, Buch Christian Jackisch, Klinikum Offenbach, Offenbach, Germany Luca Gianni, San Raffaele Institute, Milan, Italy Jose Baselga, Memorial Sloan Kettering Cancer Center, New York,
    J Clin Oncol 32:2159-65. 2014
    ..To document the rate and outcome of trastuzumab-associated cardiac dysfunction in patients following 1 or 2 years of adjuvant therapy...
  52. doi request reprint Neoadjuvant therapy as a platform for drug development and approval in breast cancer
    Aditya Bardia
    Authors Affiliations Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts and Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 19:6360-70. 2013
    ..In the years to come, we anticipate an increase in the number of neoadjuvant trials testing novel therapies that hopefully will open a new path in bringing efficacious new therapies to patients with breast cancer...
  53. ncbi request reprint Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer
    Josep Castellvi
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer 107:1801-11. 2006
    ....
  54. pmc Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
    Arkaitz Carracedo
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 118:3065-74. 2008
    ....
  55. ncbi request reprint Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine
    Joaquim Bellmunt
    Medical Oncology Sevice, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer 95:751-7. 2002
    ....
  56. doi request reprint Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics
    Teresa Macarulla
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 9:2844-52. 2010
    ..Pharmacodynamic analyses in mitotic cells of both skin and tumor provided proof of mechanism for Aurora A kinase inhibition. A more potent, selective, second-generation Aurora A kinase inhibitor, MLN8237, is in clinical development...
  57. ncbi request reprint Targeting the microtubules in breast cancer beyond taxanes: the epothilones
    Javier Cortes
    Department of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Oncologist 12:271-80. 2007
    ..The results of these studies are eagerly awaited and it is anticipated that epothilones may become an important treatment option in patients with breast cancer...
  58. doi request reprint Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study
    Aleix Prat
    Authors Affiliations Translational Genomics Group, Vall d Hebron Institute of Oncology Department of Medicine, Universitat Autonoma de Barcelona, Barcelona Hospital Clinico Universitario, Valencia, Spain Oncología Médica, San Raffaele Cancer Centre, Milan, Italy Roche, Pharma Research and Early Development, Penzberg Frauenklinik vom Roten Kreuz, Munich, Germany University of North Carolina, Chapel Hill, North Carolina NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation NN Blokhin Russian Cancer Centre Central Clinical Hospital named after N A Semashko, Moscow, Russia and Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 20:511-21. 2014
    ....
  59. doi request reprint Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors
    Kyriakos P Papadopoulos
    Authors Affiliations South Texas Accelerated Research Therapeutics, San Antonio, Texas Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, New York Sanofi, Cambridge, Massachusetts Exelixis Inc, South San Francisco, California Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan Vall d Hebron University Hospital and Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Barcelona, Spain Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia and Sanofi, Vitry sur Seine, France
    Clin Cancer Res 20:2445-56. 2014
    ....
  60. doi request reprint Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors
    Ferry A L M Eskens
    Authors Affiliations Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology VHIO, Universitat Autonoma de Barcelona, Barcelona, Spain Eisai Inc, Woodcliff Lake, New Jersey Eisai Inc, Tsukuba, Japan and Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 19:6296-304. 2013
    ..To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8, and 15 in a 28-day schedule...
  61. pmc CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity
    Ron Firestein
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 455:547-51. 2008
    ..Together these observations suggest that therapeutic interventions targeting CDK8 may confer a clinical benefit in beta-catenin-driven malignancies...
  62. doi request reprint The evolving war on cancer
    Daniel A Haber
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
    Cell 145:19-24. 2011
    ..Could this mark a turning point in the "War on Cancer"?..
  63. pmc Targeted therapies for breast cancer
    Michaela J Higgins
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Clin Invest 121:3797-803. 2011
    ..In addition, combinatorial approaches that act on the secondary mutations and/or compensatory pathways in resistant tumors may markedly improve on the effects of targeted agents used alone...
  64. doi request reprint A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases
    Josep Tabernero
    Authors Affiliations Vall d Hebron University Hospital, Vall d Hebron Institute of Oncology VHIO, Universitat Autònoma de Barcelona CRC Hospital Quirón de Barcelona, Barcelona, Spain AVEO Oncology, Cambridge, Massachusetts and Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 20:2793-804. 2014
    ....
  65. pmc Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis
    Mark M Pomerantz
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS Genet 6:e1001204. 2010
    ..More broadly, the findings demonstrate that disease risk alleles may influence multiple genes, and associations between genotype and expression may only be observed in the context of specific tissue and disease states...
  66. doi request reprint Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial
    Serena Di Cosimo
    Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 21:49-59. 2015
    ..Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin-like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination...
  67. pmc BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
    Anthony C Faber
    Massachusetts General Hospital Cancer Center, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02129, USA
    Cancer Discov 1:352-65. 2011
    ..These findings suggest assessment of BIM levels in treatment-naïve tumor biopsies may indicate the degree of benefit from single-agent kinase inhibitors in multiple oncogene-addiction paradigms...
  68. pmc Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer
    Ashish Juvekar
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Cancer Discov 2:1048-63. 2012
    ....
  69. pmc Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
    Min Yu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
    Science 339:580-4. 2013
    ..These data support a role for EMT in the blood-borne dissemination of human breast cancer...
  70. pmc A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center Weill Cornell Medical College, 300 East 66th Street, New York, NY 10065, USA
    Breast Cancer Res Treat 139:107-13. 2013
    ..The safety profile for patients on study raises the possibility of retaspimycin HCl underdosing that limited efficacy. Studies employing higher doses are ongoing...